CTRI/2017/05/008512尚未招募未知
Do patient derived organoids predict therapeutic response in pancreatic cancer patients with advanced disease.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients with metastatic pancreatic adenocarcinoma with liver metastasis
- •Treatment naive
- •Willing to consent for ultrasound guided core biopsy
- •ECOG PS 0 or 1
排除标准
- •Metastasis to CNS
- •PS or general condition does not allow FOLFIRINOX based chemotherapy
- •Refused consent for participation in study
- •Severe medical conditions or illness including HIV HBV HCV infections.
- •Inadequate organ functions.
- •Previously treated with any chemo radio biological immunotherapy.
研究者
相似试验
招募中
不适用
Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver MetastasisExplore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver MetastasesNCT05183425Changhai Hospital60
招募中
不适用
SOTO: Treatment Sensitivity of Organoids to Predict Treatment OutcomeHead and Neck Squamous Cell CarcinomaHead and Neck CancerNCT05400239Guy's and St Thomas' NHS Foundation Trust60
撤回
2 期
Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal TumorsOrganoidsNCT05378048Chinese University of Hong Kong
招募中
不适用
PDO/PDO-TIL/PDOTS for Drug ScreenMetastatic Liver CancerLiver CancerNCT05913141Shanghai Zhongshan Hospital30
已完成
不适用
Tumor organoids: feasibility to predict sensitivity to treatment in cancer patients (TUMOROID trial)breast)colorectaldisseminated cancer (lungMetastatic cancer10027476NL-OMON44690ederlands Kanker Instituut665